Scarica l'app Stockscreener
5.94
2.24%
0.13
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché MNKD Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$5.81
Aprire:
$5.83
Volume 24 ore:
3.39M
Relative Volume:
0.86
Capitalizzazione di mercato:
$1.82B
Reddito:
$248.37M
Utile/perdita netta:
$11.74M
Rapporto P/E:
118.80
EPS:
0.05
Flusso di cassa netto:
$18.24M
1 W Prestazione:
+4.58%
1M Prestazione:
+13.14%
6M Prestazione:
+55.09%
1 anno Prestazione:
-9.31%
Intervallo 1D:
$5.785
$6.01
Intervallo di 1 settimana:
$5.585
$6.01
Portata 52W:
$3.3812
$7.07
Mannkind Corp Stock (MNKD) Company Profile
Nome
Mannkind Corp
Settore
Industria
Telefono
818-661-5000
Indirizzo
1 CASPER STREET, DANBURY, CA
Confronta MNKD con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MNKD
Mannkind Corp
|
5.94 | 1.78B | 248.37M | 11.74M | 18.24M | 0.05 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Mannkind Corp Stock (MNKD) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-11-24 | Iniziato | Truist | Buy |
| 2025-11-13 | Iniziato | Leerink Partners | Outperform |
| 2025-10-20 | Iniziato | Wells Fargo | Overweight |
| 2025-10-10 | Iniziato | Leerink Partners | Outperform |
| 2025-07-16 | Ripresa | H.C. Wainwright | Buy |
| 2025-04-10 | Iniziato | Mizuho | Outperform |
| 2025-02-10 | Iniziato | Wedbush | Outperform |
| 2024-12-20 | Iniziato | Wells Fargo | Overweight |
| 2024-12-19 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-09-09 | Ripresa | Leerink Partners | Outperform |
| 2024-06-13 | Iniziato | Rodman & Renshaw | Buy |
| 2023-10-10 | Iniziato | Wedbush | Outperform |
| 2021-05-14 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2019-12-24 | Iniziato | Oppenheimer | Outperform |
| 2019-10-25 | Iniziato | Cantor Fitzgerald | Overweight |
| 2019-05-14 | Iniziato | BTIG Research | Buy |
| 2019-03-04 | Iniziato | SVB Leerink | Outperform |
| 2019-02-22 | Iniziato | SVB Leerink | Outperform |
| 2018-02-28 | Downgrade | Maxim Group | Hold → Sell |
| 2017-11-01 | Downgrade | Maxim Group | Buy → Hold |
| 2017-10-10 | Iniziato | H.C. Wainwright | Buy |
| 2017-10-06 | Reiterato | Maxim Group | Buy |
| 2017-08-11 | Iniziato | Maxim Group | Buy |
| 2016-05-10 | Reiterato | Piper Jaffray | Underweight |
| 2016-05-10 | Reiterato | RBC Capital Mkts | Underperform |
| 2016-01-06 | Reiterato | Piper Jaffray | Underweight |
| 2016-01-06 | Reiterato | RBC Capital Mkts | Underperform |
| 2015-11-04 | Downgrade | RBC Capital Mkts | Outperform → Underperform |
| 2015-09-09 | Downgrade | Piper Jaffray | Neutral → Underweight |
| 2015-08-03 | Reiterato | RBC Capital Mkts | Outperform |
| 2015-05-11 | Downgrade | JP Morgan | Neutral → Underweight |
| 2015-05-11 | Reiterato | MLV & Co | Hold |
| 2015-04-16 | Reiterato | RBC Capital Mkts | Outperform |
Mostra tutto
Mannkind Corp Borsa (MNKD) Ultime notizie
MannKind stock price target raised to $9 by Leerink on Tyvaso DPI royalties - Investing.com
MannKind (NASDAQ:MNKD) CEO Michael Castagna Sells 107,920 Shares of Stock - MarketBeat
MannKind (MNKD) Valuation Check After FDA Filing Progress for FUROSCIX ReadyFlow Autoinjector - simplywall.st
Mannkind EVP Thomson sells $823k in shares By Investing.com - Investing.com South Africa
Insider Selling: Michael Castagna Sells Shares of MannKind Corp (MNKD) - GuruFocus
Mannkind EVP Thomson sells $823k in shares - Investing.com
Mannkind CEO Castagna sells $601k in shares By Investing.com - Investing.com UK
Mannkind CEO Castagna sells $601k in shares - Investing.com
MannKind Corp Executives Sell Shares - TradingView
VP Thomson Sells 147,780 ($823.1K) Of MannKind Corp [MNKD] - TradingView
Is MannKind Corporation (NNFN) stock undervalued after correctionWeekly Investment Report & Growth Focused Stock Reports - Newser
How MannKind Corporation (NNFN) stock moves in volatile trading sessionsJuly 2025 EndofMonth & Weekly Momentum Stock Picks - Newser
Is There Now an Opportunity in MannKind After This Year’s Share Price Pullback? - Yahoo Finance
MAI Capital Management Reduces Stock Holdings in MannKind Corporation $MNKD - MarketBeat
Can MannKind Corporation (NNFN) stock attract analyst upgradesQuarterly Profit Report & AI Based Buy and Sell Signals - Newser
Can MannKind Corporation (NNFN) stock sustain double digit ROEMarket Movement Recap & Long Hold Capital Preservation Plans - Newser
FDA Reviewing 10-Second Treatment for Edema in Heart Failure - Diagnostic and Interventional Cardiology
MannKind (MNKD) Awaits FDA Decision on Furoscix Autoinjector - GuruFocus
FDA accepts MannKind’s sNDA for ReadyFlow Autoinjector - Investing.com
MannKind (MNKD) Awaits FDA Decision on FUROSCIX ReadyFlow Autoin - GuruFocus
MannKind Announces U.S. FDA Accepts for Review its Supplemental New Drug Application (sNDA) of FUROSCIX ReadyFlow™ Autoinjector for the Treatment of Edema in Adults with Chronic Heart Failure or Chronic Kidney Disease - The Manila Times
MannKind Corporation Announces FDA Acceptance of sNDA for FUROSCIX ReadyFlow™ Autoinjector, Targeting Improved Management of Chronic Heart Failure and Kidney Disease - Quiver Quantitative
MannKind (Nasdaq: MNKD) lands FDA sNDA review, PDUFA July 26, 2026 for ReadyFlow - Stock Titan
Geode Capital Management LLC Grows Position in MannKind Corporation $MNKD - MarketBeat
MannKind (MNKD) Is Up 6.4% After Wave of Analyst Upgrades Despite MNKD-101 Discontinuation – Has The Bull Case Changed? - simplywall.st
Truist Securities Initiates Coverage on MNKD with 'Buy' Rating a - GuruFocus
MannKind stock initiated with Buy rating at Truist on Tyvaso DPI potential By Investing.com - Investing.com South Africa
MannKind stock initiated with Buy rating at Truist on Tyvaso DPI potential - Investing.com
MannKind Corporation (NASDAQ:MNKD) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Will MannKind Corporation stock outperform value stocksMarket Activity Recap & Accurate Intraday Trading Signals - newser.com
Is MannKind Corporation (NNFN) stock a contrarian opportunityPortfolio Risk Report & Intraday High Probability Alerts - newser.com
Why MannKind Corporation (NNFN) stock attracts wealthy investorsTrend Reversal & Safe Entry Momentum Tips - newser.com
What momentum indicators show for MannKind Corporation stock2025 Earnings Impact & Step-by-Step Trade Execution Guides - newser.com
How MannKind Corporation stock performs after earningsJuly 2025 PreEarnings & Weekly High Momentum Picks - newser.com
How MannKind Corporation (NNFN) stock trades under stagflationMarket Activity Report & Free Technical Confirmation Trade Alerts - newser.com
Is MannKind Corporation (NNFN) stock attractive post correction2025 Fundamental Recap & Verified Short-Term Plans - newser.com
MannKind at Jefferies London Healthcare Conference: Strategic Growth Insights By Investing.com - Investing.com Nigeria
Is MannKind Corporation stock cheap compared to fundamentalsShare Buyback & Safe Swing Trade Setups - newser.com
MannKind at Jefferies London Healthcare Conference: Strategic Growth Insights - Investing.com India
Is MannKind Corporation (NNFN) stock a safe buy pre earnings2025 Top Decliners & AI Driven Stock Reports - newser.com
Technical signs of recovery in MannKind CorporationTrade Ideas & Stepwise Trade Signal Implementation - newser.com
Mitsubishi UFJ Asset Management Co. Ltd. Buys Shares of 67,889 MannKind Corporation $MNKD - MarketBeat
SBI Securities Co. Ltd. Acquires 65,184 Shares of MannKind Corporation $MNKD - MarketBeat
Mannkind Corp Azioni (MNKD) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Mannkind Corp Azioni (MNKD) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Castagna Michael | Chief Executive Officer |
Dec 02 '25 |
Option Exercise |
4.55 |
107,920 |
491,036 |
2,612,712 |
| Castagna Michael | Chief Executive Officer |
Dec 02 '25 |
Sale |
5.57 |
107,920 |
601,114 |
2,504,792 |
| Thomson David | EVP Genl Counsel & Secretary |
Dec 02 '25 |
Option Exercise |
4.58 |
147,780 |
676,788 |
989,499 |
| Thomson David | EVP Genl Counsel & Secretary |
Dec 02 '25 |
Sale |
5.57 |
147,780 |
823,135 |
841,719 |
1.08%
0.91%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):